Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Oct;6(5 Suppl 2):S136-7.
doi: 10.5489/cuaj.12202.

Male lower urinary tract symptoms associated with overactive bladder

Marcus J Drake  1
Affiliations

Male lower urinary tract symptoms associated with overactive bladder

Marcus J Drake. Can Urol Assoc J. 2012 Oct.

Abstract

Lower urinary tract symptoms (LUTS) associated with overactive bladder (OAB) are more likely to respond to antimuscarinic therapy than to alpha blockade. As such, initial treatment of men with storage symptoms should incorporate an antimuscarinic agent. For men who are truly refractory to current pharmacotherapies, there is emerging evidence to support the use of botulinum toxin A.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Antimuscarinic + alpha-blocker in male lower urinary tract symptoms: Effect on total urgency score. TOCAS: tamsulosin oral controlled absorption system; sol: solifenacin.
Fig. 2
Fig. 2
Antimuscarinic monotherapy for men with overactive bladder.
See this image and copyright information in PMC

References

    1. Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO) European Association of Urology. 2012. http://www.uroweb.org/gls/pdf/12_Male_LUTS_LR.pdf (Accessed July 31, 2012).
    1. Drake M, Chapple C, van Kerrebroeck P, et al. Efficacy of combination therapy with tamsulosin OCAS and solifenacin in NEPTUNE: Results from a randomised, phase 3 trial in men with LUTS. Eur Urol. 2012 EAU Abstracts #746.
    1. Van Kerrebroeck P, Steers W, Haab F. Establishing effective treatment of overactive bladder symptoms in men [abstract #233] Eur Urol Suppl. 2005;3:61. doi: 10.1016/S1569-9056(05)80241-6. - DOI
    1. Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3Pt1):999–1004. doi: 10.1016/S0022-5347(05)00483-0. - DOI - PubMed
    1. Lee KS, Choo MS, Kim DY, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol. 2005;174(4Pt1):1334–8. doi: 10.1097/01.ju.0000173630.94559.fd. - DOI - PubMed

LinkOut - more resources